ANTHEM

Anthem Biosciences Share Price

 

 

Invest in Anthem Biosciences with 3.39X leverage

Invest with MTF

Performance

  • Low
  • ₹686
  • High
  • ₹708
  • 52 Week Low
  • ₹668
  • 52 Week High
  • ₹874
  • Open Price₹690
  • Previous Close₹686
  • Volume151,840

Investment Returns

  • Over 1 Month -12.71%
  • Over 3 Month -5.98%
  • Over 6 Month + 22.63%
  • Over 1 Year + 22.63%

Smart Investing Starts Here Start SIP with Anthem Biosciences for Steady Growth!

Invest Now

Anthem Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 39,257
  • P/B Ratio
  • 16.3
  • Average True Range
  • 21.92
  • EPS
  • 9.19
  • Dividend Yield
  • 0
  • MACD Signal
  • -22.09
  • RSI
  • 33.68
  • MFI
  • 10.59

Anthem Biosciences Financials

Anthem Biosciences Technicals

EMA & SMA

Current Price
₹699.00
+ 12.6 (1.84%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 2
  • 20 Day
  • ₹720.58
  • 50 Day
  • ₹750.02
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

685.95 Pivot Speed
  • R3 703.80
  • R2 697.70
  • R1 692.05
  • S1 680.30
  • S2 674.20
  • S3 668.55

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anthem Biosciences is a Contract Research and Innovation Service Provider (CRISP) in Bangalore, India, with two facilities supporting over 1,000 researchers. It offers R&D, manufacturing, and testing of biologics, small molecules, and nutraceuticals, serving global pharma, biotech, and wellness companies.

Anthem Biosciences Ltd has an operating revenue of Rs. 1,912.03 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 36% is great, ROE of 18% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 87 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anthem Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-08 Quarterly Results
2025-08-13 Quarterly Results

Anthem Biosciences F&O

Anthem Biosciences Shareholding Pattern

74.69%
6.68%
0.42%
1.66%
0%
9.61%
6.94%

Anthem Biosciences FAQs

Anthem Biosciences share price is ₹699 As on 13 November, 2025 | 09:52

The Market Cap of Anthem Biosciences is ₹39256.5 Cr As on 13 November, 2025 | 09:52

The P/E ratio of Anthem Biosciences is As on 13 November, 2025 | 09:52

The PB ratio of Anthem Biosciences is 16.3 As on 13 November, 2025 | 09:52

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23